Malta - anglès - Medicines Authority

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - yellow fever, virus strain, d - powder and solvent for suspension for injection - yellow fever virus strain 17d 1000 iu - vaccines

Nova Zelanda - anglès - Ministry for Primary Industries

new zealand bloodstock ltd - japanese encephalitis virus - japanese encephalitis virus 0 vaccine - vaccine

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

sanofi pasteur - yellow fever virus 17 d-204 strain - powder and solvent for suspension for injection in pre-filled syringe - 1000 international unit(s) - yellow fever vaccines; yellow fever, live attenuated

Estats Units - anglès - NLM (National Library of Medicine)

valneva scotland ltd. - japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) (unii: dz854i04ze) (japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) - unii:dz854i04ze) - japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) 6 ug in 0.5 ml - ixiaro is a vaccine indicated for the prevention of disease caused by japanese encephalitis virus (jev). ixiaro is approved for use in individuals 2 months of age and older. severe allergic reaction (e.g., anaphylaxis) after a previous dose of ixiaro, any other japanese encephalitis virus vaccine, or any component of ixiaro, including protamine sulfate, is a contraindication to administration of ixiaro [see description (11)]. alternatively, because of uncertainty as to which component of the vaccine may be responsible, individuals with a history of severe allergic reaction to another japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with ixiaro is considered. pregnancy category b. reproduction studies have been performed in female rats at doses approximately 300-fold excess relative to the projected human dose (on a mg/kg basis) and have revealed no evidence of impaired fertility or harm to the fetus due to ixiaro. there are, however, no adequate and well‑controlled

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - yellow fever virus, quantity: 1000 pfu e.1000 mouse ld50 - injection, powder for - excipient ingredients: calcium chloride dihydrate; magnesium sulfate heptahydrate; histidine hydrochloride; sodium chloride; dibasic sodium phosphate dihydrate; alanine; sorbitol; potassium chloride; lactose monohydrate; monobasic potassium phosphate; sodium hydroxide - prevention of yellow fever. vaccination is recommended for:,? every individual aged 9 months and over living or travelling through an endemic area with a current or periodic risk of yellow fever transmission. ? non-vaccinated individual moving from an endemic area with a current or periodic risk of yellow fever transmission to a potentially receptive non-endemic area with a current or periodic risk of yellow fever transmission. ? laboratory workers handling potentially infectious materials. in order to be officially recognised, the yellow fever vaccination must be administered in an approved vaccination centre and registered on an international certificate. the validity period of the certificate is established according to international health regulations recommendations and starts 10 days after primary vaccination and immediately after re-vaccination.

Canadà - anglès - Health Canada

valneva austria gmbh - inact.japanese encephal virus(attenuat. strain sa14-14-2 produced in vero cells) - suspension - 6mcg - inact.japanese encephal virus(attenuat. strain sa14-14-2 produced in vero cells) 6mcg - vaccines

Malàisia - anglès - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - live, attenuated yellow fever virus -

Singapur - anglès - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - live attenuated yellow fever virus strain 17 d - injection - live attenuated yellow fever virus strain 17 d not less than 1000 iu

Estats Units - anglès - NLM (National Library of Medicine)

sanofi pasteur inc. - yellow fever virus strain 17d-204 live antigen (unii: py4eet359t) (yellow fever virus strain 17d-204 live antigen - unii:py4eet359t) - yellow fever virus strain 17d-204 live antigen 4.74 [pfu] in 0.5 ml - yf-vax is indicated for active immunization for the prevention of yellow fever in persons 9 months of age and older in the following categories: while the actual risk for contracting yellow fever during travel is probably low, variability of itineraries, behaviors and seasonal incidence of disease make it difficult to predict the actual risk for a given individual living in or traveling to a known endemic or epidemic area. greater risk is associated with living in or traveling to areas of south america and africa where yellow fever infection is officially reported at the time of travel and with traveling outside the urban areas of countries that do not officially report the disease but that lie in a yellow fever endemic zone. some countries require an individual to have a valid international certificate of vaccination or prophylaxis (icvp) if the individual has been in countries either known or thought to harbor yellow fever virus. the certificate becomes valid 10 days after vaccination with yf-vax. (13) (14)

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

imported (korea) - japanese encephalitis virus - solution for injection